Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Lifeward ( (LFWD) ) is now available.
On February 19, 2026, Lifeward Ltd. entered into an Intellectual Property Assignment and Technology Transfer Agreement with Israeli company Skelable Ltd., under which Lifeward will acquire specified intellectual property, related technology assets and bring on certain key Skelable employees. As consideration, Lifeward will pay up to $500,000 in three milestone-based installments, the vast majority in newly issued ordinary shares priced to market and a small portion in cash, with share issuance relying on a private placement exemption and the initial closing expected in the near term, signaling a strategic expansion of Lifeward’s technology base and talent pool with limited cash outlay.
The transaction structure underscores Lifeward’s effort to strengthen its intellectual property portfolio while conserving cash, potentially enhancing its competitive position in medical technology and supporting future product development. For Skelable stakeholders, the deal provides equity exposure to Lifeward’s public market valuation, while investors in Lifeward gain visibility into a targeted technology acquisition strategy intended to leverage new assets and personnel for operational and innovation synergies.
The most recent analyst rating on (LFWD) stock is a Hold with a $0.65 price target. To see the full list of analyst forecasts on Lifeward stock, see the LFWD Stock Forecast page.
Spark’s Take on LFWD Stock
According to Spark, TipRanks’ AI Analyst, LFWD is a Neutral.
The score is held down primarily by very weak profitability and heavy cash burn despite solid revenue growth and low debt. Technicals are neutral with only modest improving momentum, and valuation is constrained by ongoing losses (negative P/E). Offsetting factors include operational improvements and guidance reaffirmation from the earnings call plus liquidity/strategic support from the Oramed-related financing and transactions, albeit with dilution and control-risk tradeoffs.
To see Spark’s full report on LFWD stock, click here.
More about Lifeward
Lifeward Ltd. operates in the medical and rehabilitation technology sector, focusing on developing and commercializing advanced assistive and mobility solutions. The company targets patients with mobility impairments and related clinical markets, positioning itself as an innovation-driven player leveraging proprietary technologies and specialized engineering expertise in its niche.
Average Trading Volume: 44,422
Technical Sentiment Signal: Sell
Current Market Cap: $7.64M
See more insights into LFWD stock on TipRanks’ Stock Analysis page.